glp-1 breast cancer New study examines drugs and a reduction in risk https://www.goodmorningamerica.com/news/story GLP-1 use could help lower

And AI has now made this trivial

But factors like user error and some designer drugs can skew the results

[DOI] [PubMed] [Google Scholar] 31.Hogan A

The Bridge currently covers the following GLP-1 medications when prescribed for weight management: Wegovy (injection and pills) Zepbound (KwikPen only) Foundayo (pills) Important note on Zepbound: Only the Zepbound KwikPen is covered under the Bridge

Prior Authorization (PA) Criteria: Implementing strong, evidence-based prior authorization criteria is crucial to manage access responsibly

Typically 2 to 4 weeks for an initial decision, extending to 6 to 10 weeks if denied and appealed